Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

XBRL 30 June 2020 filed with the SEC

September 16, 2020September 16, 2020 Alterity Therapeutics

XBRL 30 June 2020 filed with the SEC

Post navigation

New data independently confirms and extends laboratory findings and expands safety profile of ATH434

Alterity raises $35M in placement to international and Australian institutions and sophisticated investors.

Related Posts

New data independently confirms and extends laboratory findings and expands safety profile of ATH434

August 4, 2020May 19, 2021

Alterity Therapeutics’ Finance News Network Presentation

July 9, 2019July 9, 2019

Alterity Therapeutics Launches to Asian Investors

April 10, 2019

Recent Posts

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
Alterity to Present at Life Sciences Investor Forum
Alterity Therapeutics to Present at the GCFF Virtual Conference 2022 – Investing in Healthcare
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065